阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期

环球市场播报07-27 21:06

　　阿斯利康今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。

　　该试验纳入局部晚期或转移性胃癌、胃食管结合部癌或食管腺癌患者，要求肿瘤细胞CLDN18.2表达≥25%。试验达到双重主要终点之一——三线及后线治疗中的总生存期，同时关键次要终点——二线及后线总体人群的总生存期也显示出显著改善。不过，另一主要终点无进展生存期虽呈改善趋势，但未达到统计学显著性。

　　在安全性方面，Sone-Ve耐受性良好，与已知安全性特征一致，未发现新的安全信号。

　　CLDN18.2已成为胃癌的重要治疗靶点，约60%的胃食管癌患者肿瘤细胞表达该蛋白。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。详细数据将在即将召开的医学会议上公布并递交监管机构。

海量资讯、精准解读，尽在新浪财经APP

责任编辑：张俊 SF065

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2654048711?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-27 21:06","share_image_url":"https://static.laohu8.com/b0d1b7e8843deea78cc308b15114de44","id":"2654048711","market":"other","top_or_hot":-1,"title":"阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期","media":"环球市场播报","content":"<html><body><div>\n<p>　　<span><a href=\"https://laohu8.com/S/AZN\">阿斯利康</a></span><span></span>今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。</p>\n<p>　　该试验纳入局部晚期或转移性胃癌、胃食管结合部癌或食管腺癌患者，要求肿瘤细胞CLDN18.2表达≥25%。试验达到双重主要终点之一——三线及后线治疗中的总生存期，同时关键次要终点——二线及后线总体人群的总生存期也显示出显著改善。不过，另一主要终点无进展生存期虽呈改善趋势，但未达到统计学显著性。</p>\n<p>　　在安全性方面，Sone-Ve耐受性良好，与已知安全性特征一致，未发现新的安全信号。</p>\n<p>　　CLDN18.2已成为胃癌的重要治疗靶点，约60%的胃食管癌患者肿瘤细胞表达该蛋白。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。详细数据将在即将召开的医学会议上公布并递交监管机构。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：张俊 SF065</p>\n</div></body></html>","source":"sina","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n阿斯利康Sone-Ve在晚期胃癌III期试验中显著延长总生存期\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<p>　　<span><a href=\"https://laohu8.com/S/AZN\">阿斯利康</a></span><span></span>今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。</p>\n<p>　　该试验纳入局部晚期或转移性胃癌、胃食管结合部癌或食管腺癌患者，要求肿瘤细胞CLDN18.2表达≥25%。试验达到双重主要终点之一——三线及后线治疗中的总生存期，同时关键次要终点——二线及后线总体人群的总生存期也显示出显著改善。不过，另一主要终点无进展生存期虽呈改善趋势，但未达到统计学显著性。</p>\n<p>　　在安全性方面，Sone-Ve耐受性良好，与已知安全性特征一致，未发现新的安全信号。</p>\n<p>　　CLDN18.2已成为胃癌的重要治疗靶点，约60%的胃食管癌患者肿瘤细胞表达该蛋白。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。详细数据将在即将召开的医学会议上公布并递交监管机构。</p>\n<div>\n<div><img src=\"\"/></div>\n<div>海量资讯、精准解读，尽在新浪财经APP</div>\n</div>\n<p>责任编辑：张俊 SF065</p>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhckx3037081.shtml\">环球市场播报</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443978.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","start_time":0,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-07-27/doc-inikhckx3037081.shtml","article_id":"2654048711","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2654048711","pubTimestamp":1785157560,"columns":[],"sourceInfo":{"source_id":"sina","name":"sina"},"weMediaInfo":null,"summary":"阿斯利康今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。","collect":0,"end_time":0,"defaultTopTitle":"sina.com.cn","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4568":"美国抗疫概念","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","BK4134":"信息科技咨询与其它服务","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","BK4007":"制药","LU1829250122.USD":"高盛欧洲核心股票组合Acc","AZNH":"ASTRAZENECA PLC ADRhedged","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","AZN":"阿斯利康","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","III":"信息服务","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A"},"translate_title":"AstraZeneca Sone-Ve significantly prolongs overall survival in advanced gastric cancer phase III trial","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"III":1.5,"AZNH":0.6,"AZN":1.5},"content_text":"阿斯利康今日公布，其潜在同类首创CLDN18.2靶向抗体偶联药物Sone-Ve在III期CLARITY-Gastric01试验中达到主要终点，与研究者选择的治疗方案相比，在二线及后线CLDN18.2阳性晚期胃癌患者中实现了具有统计学显著性和高度临床意义的总生存期改善。\n　　该试验纳入局部晚期或转移性胃癌、胃食管结合部癌或食管腺癌患者，要求肿瘤细胞CLDN18.2表达≥25%。试验达到双重主要终点之一——三线及后线治疗中的总生存期，同时关键次要终点——二线及后线总体人群的总生存期也显示出显著改善。不过，另一主要终点无进展生存期虽呈改善趋势，但未达到统计学显著性。\n　　在安全性方面，Sone-Ve耐受性良好，与已知安全性特征一致，未发现新的安全信号。\n　　CLDN18.2已成为胃癌的重要治疗靶点，约60%的胃食管癌患者肿瘤细胞表达该蛋白。晚期胃癌患者预后极差，一线治疗进展后中位生存期仅5-9个月。阿斯利康肿瘤研发执行副总裁Susan Galbraith表示，Sone-Ve有望通过新型靶向ADC替代传统化疗，重塑胃癌治疗格局。详细数据将在即将召开的医学会议上公布并递交监管机构。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：张俊 SF065","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2654048711","isCrawlerRequest":true}